All eyes are on May 5th. When BioNTech reports its first-quarter earnings, investors will scrutinize more than just revenue from fading COVID-19 vaccine sales. The update will serve as a crucial progress check on the company’s multi-billion-euro pivot from a pandemic player to a full-fledged oncology contender.
The financial runway for this ambitious transformation is substantial. The company entered 2026 with approximately EUR 17.2 billion in cash and marketable securities. This massive war chest is designed to fund an aggressive clinical push while absorbing significant losses, including a net loss of EUR 1.14 billion reported for the previous year. The key question for the upcoming call is whether management can convincingly frame its Q1 spending within the context of its full-year strategic goals.
Central to that strategy is an unprecedented expansion of late-stage trials. BioNTech aims to have 15 active Phase 3 clinical studies running by the end of this year, a cornerstone metric for its goal of achieving ten approved cancer indications by 2030. The first major commercial milestone is the targeted launch of its first proprietary cancer immunotherapy by the end of 2026.
Recent clinical readouts have provided tangible momentum. The antibody-drug conjugate Trastuzumab Pamirtecan, developed with DualityBio, recently showed a confirmed objective response rate of 49.3% in a Phase 2 trial for HER2-positive endometrial cancer, a notable result in a hard-to-treat patient population. Another candidate, the bispecific antibody BNT327, is also a key hope. Furthermore, long-term data for the pancreatic cancer vaccine candidate autogene cevumeran (BNT122) revealed that nearly 90% of immunological responders were still alive up to six years post-treatment in an early-stage study.
Should investors sell immediately? Or is it worth buying BioNTech?
This pipeline progress has resonated with the market. BioNTech’s share price has climbed over 22% since its mid-March low of EUR 72.50, currently trading around EUR 89. Over the past 30 days alone, the stock has gained more than 16%. However, it remains well below its 52-week high of nearly EUR 106, indicating lingering investor caution.
A significant source of that uncertainty is leadership. Founders Ugur Sahin and Özlem Türeci plan to depart the management board by the end of 2026 to build a new, independent biotech venture focused on next-generation mRNA innovations. While BioNTech will retain a minority stake and rights to certain technologies in the new project, the board’s search for successors is ongoing. Analysts expect clear communication on the leadership transition during the earnings conference call, as unresolved questions could weigh on the stock regardless of the quarterly figures.
The upcoming report arrives amid shifting institutional ownership. In the fourth quarter of last year, Pfizer divested over 1.6 million BioNTech shares. With seven key data readouts from late-stage studies expected throughout 2026, BioNTech’s Q1 update on May 5th at 2:00 PM CET will set the tone for a pivotal year, testing its ability to balance high research costs against declining vaccine revenue.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 21 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 21.
BioNTech: Buy or sell? Read more here...
